GERD and Silent Reflux (LPR): Why Acid Blockers Aren't the Whole Answer

Classic GERD shows up as heartburn and regurgitation. LPR (laryngopharyngeal reflux, or “silent reflux”) often has no heartburn at all — instead you get chronic throat clearing, hoarseness, a lump sensation, post-nasal drip, or a lingering cough. Many people with LPR are told their reflux is “mild” because they don't feel classic heartburn, when in fact the reflux is reaching tissue that's far more sensitive than the stomach.

PPIs reduce how much acid your stomach makes. That can ease the burning. But reflux contains more than acid — it carries pepsin, an enzyme that can cling to and irritate the delicate tissue of the throat and esophagus even when acid is suppressed. This is a leading reason silent reflux so often shrugs off acid medication: you've lowered the acid, but the tissue irritation and the underlying inflammation are still in play.

And because acid plays real roles in digestion, suppressing it long-term has its own tradeoffs. Many people are looking for a way to support the irritated tissue itself, not just turn the acid down further.

The trials do not give one answer. In TOPPITS, a 16-week trial of 346 adults with persistent throat symptoms, people on lansoprazole did not report better outcomes than people on placebo¹. In a three-month trial of 62 patients with LPR, esomeprazole gave a significantly greater improvement in symptoms and laryngeal appearance than placebo, although the authors noted a high placebo effect⁶. A pooled analysis of 14 randomized trials (771 people) found a higher response rate on a PPI than on placebo, but no advantage on the reflux finding score².

Reflux also carries pepsin. In lab tests, human pepsin stayed stable at neutral pH and could be reactivated when acid returned³. In cultured laryngeal epithelial cells, pepsin raised reactive oxygen species and the inflammatory signals NLRP3 and IL-1β in a dose-dependent manner⁷.

Sulforaphane activates the Nrf2 pathway — the body's master switch for antioxidant and anti-inflammatory defenses. The tissues that reflux irritates are under repeated oxidative and inflammatory stress, and Nrf2 activation helps those cells defend and maintain themselves. Rather than only reducing acid, this supports the resilience of the tissue taking the damage.

It's a different lever entirely — working with the body's own protective systems in the throat, esophagus, and stomach lining.

Sulforaphane isn't pre-formed in the plant. It's created when the precursor glucoraphanin meets the enzyme myrosinase.⁸ Most supplements include only glucoraphanin — the enzyme is destroyed in manufacturing — and rely on your gut bacteria to finish the conversion, which is unreliable. No enzyme, little sulforaphane.

Sproutly delivers the enzyme directly so conversion actually happens:

• Broccoli Seed Extract (13% glucoraphanin) — the precursor
• Broccoli Sprout Extract with active myrosinase — the enzyme delivered directly
• Mustard Seed Extract — a natural backup enzyme source
• Vitamin C — supports conversion

Up to 30mg of real sulforaphane per serving, produced fresh in the body — vegan, non-GMO, and clean-label.

One small study recruited 16 adults with heartburn or GERD complaints who were not taking a PPI. Each person took a commercial broccoli seed and sprout extract tablet that contains glucoraphanin plus active myrosinase, first before and then during a course of omeprazole, and the researchers measured sulforaphane and its metabolites in urine⁵.

The tablets converted about 26% of the glucoraphanin before omeprazole and about 34% during it⁵.

Sulforaphane supports the body gradually. Most people take it daily for several weeks before noticing changes, since it works by strengthening the body's own defenses over time. It is daily support, not an instant fix, and not a replacement for medical care — don't stop prescribed reflux medication without talking to your doctor.

1. Wilson JA, Stocken DD, Watson GC, et al. Lansoprazole for persistent throat symptoms in secondary care: the TOPPITS RCT. Health Technol Assess. 2021;25(3):1-118. PMID 33492208
2. Guo H, Ma H, Wang J. Proton pump inhibitor therapy for the treatment of laryngopharyngeal reflux: a meta-analysis of randomized controlled trials. J Clin Gastroenterol. 2016;50(4):295-300. PMID 25906028
3. Johnston N, Dettmar PW, Bishwokarma B, Lively MO, Koufman JA. Activity/stability of human pepsin: implications for reflux attributed laryngeal disease. Laryngoscope. 2007;117(6):1036-9. PMID 17417109
4. Houghton CA, Fassett RG, Coombes JS. Sulforaphane and other nutrigenomic Nrf2 activators: can the clinician's expectation be matched by the reality? Oxid Med Cell Longev. 2016;2016:7857186. PMID 26881038
5. Fahey JW, Wade KL, Stephenson KK, et al. Bioavailability of sulforaphane following ingestion of glucoraphanin-rich broccoli sprout and seed extracts with active myrosinase: a pilot study of the effects of proton pump inhibitor administration. Nutrients. 2019;11(7):1489. PMID 31261930
6. Reichel O, Dressel H, Wiederänders K, Issing WJ. Double-blind, placebo-controlled trial with esomeprazole for symptoms and signs associated with laryngopharyngeal reflux. Otolaryngol Head Neck Surg. 2008;139(3):414-20. PMID 18722223
7. Tan JJ, Dai YF, Wang F, et al. Pepsin-mediated inflammation in laryngopharyngeal reflux via the ROS/NLRP3/IL-1β signaling pathway. Cytokine. 2024;178:156568. PMID 38471420
8. Fahey JW, Holtzclaw WD, Wehage SL, et al. Sulforaphane bioavailability from glucoraphanin-rich broccoli: control by active endogenous myrosinase. PLoS One. 2015;10(11):e0140963. PMID 26524341